<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="letter"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Ann Med</journal-id><journal-id journal-id-type="iso-abbrev">Ann Med</journal-id><journal-title-group><journal-title>Annals of Medicine</journal-title></journal-title-group><issn pub-type="ppub">0785-3890</issn><issn pub-type="epub">1365-2060</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40391415</article-id><article-id pub-id-type="pmc">PMC12093794</article-id><article-id pub-id-type="doi">10.1080/07853890.2025.2504708</article-id><article-id pub-id-type="publisher-id">2504708</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version><article-categories><subj-group subj-group-type="article-type"><subject>Letter to the Editor</subject></subj-group><subj-group subj-group-type="heading"><subject>Emergency Medicine</subject></subj-group></article-categories><title-group><article-title>Letter to the editor regarding &#x0201c;effects of adjunctive milrinone versus placebo on hemodynamics in patients with septic shock: a randomized controlled trial&#x0201d;</article-title><subtitle>Milrinone in septic shock: hemodynamic improvement without mortality benefit</subtitle><alt-title alt-title-type="left-running-head">M. Hasan and H. S. Ali</alt-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0006-0107-5065</contrib-id><name><surname>Hasan</surname><given-names>Muhammad</given-names></name><degrees>MBBS</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="AN0001" ref-type="corresp"/><xref rid="AF0001" ref-type="aff"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0009-0009-4395-6532</contrib-id><name><surname>Ali</surname><given-names>Haya S.</given-names></name><degrees>MBBS</degrees><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term="Writing &#x02013; review &#x00026; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="AF0001" ref-type="aff"/></contrib><aff id="AF0001"><institution>Dow International Medical College</institution>, <city>Karachi</city>, <country>Pakistan</country></aff></contrib-group><author-notes><corresp id="AN0001">
<email xlink:href="mailto:hasanakbani.2000@gmail.com">hasanakbani.2000@gmail.com</email>
</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>20</day><month>5</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>20</day><month>5</month><year>2025</year></pub-date><volume>57</volume><issue>1</issue><elocation-id>2504708</elocation-id><pub-history><event event-type="received"><date><day>1</day><month>4</month><year>2025</year></date></event><event event-type="accepted"><date><day>6</day><month>4</month><year>2025</year></date></event><event event-type="tagger"><event-desc>KnowledgeWorks Global Ltd.</event-desc><date><day>20</day><month>5</month><year>2025</year></date></event><event event-type="build-issue-online"><event-desc>published online in a building issue</event-desc><date><day>20</day><month>5</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#x000a9; 2025 The Author(s). Published by Informa UK Limited, trading as Taylor &#x00026; Francis Group</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="IANN_57_2504708.pdf"/><support-group><funding-group><funding-statement>This research received no specific grant from any funding agency, commercial, or not-for-profit organization.</funding-statement></funding-group></support-group><counts><fig-count count="0"/><table-count count="0"/><page-count count="2"/><word-count count="781"/></counts></article-meta></front><body><p>In this issue of <italic toggle="yes">Annals of Medicine</italic>, Tongyoo et&#x000a0;al. [<xref rid="CIT0001" ref-type="bibr">1</xref>] conducted a randomized controlled trial investigating the effects of adjunctive milrinone on haemodynamics in patients with septic shock. The authors found that milrinone improved cardiac output compared to placebo in patients with persistent tissue hypoperfusion or impaired left ventricular function. However, we would like to emphasize two key findings that have significant implications for the interpretation of these results and their application in clinical practice.</p><p>First, despite the improvement in cardiac output, Tongyoo et&#x000a0;al. found no significant difference in mortality (28-day, ICU, or hospital) between the milrinone and placebo groups. This finding is consistent with previous research that has questioned the link between hemodynamic improvement and survival in septic shock. For example, the ALBIOS study, a large randomized trial comparing albumin and crystalloid solutions for fluid resuscitation in severe sepsis and septic shock, also found that targeting higher mean arterial pressure and cardiac index did not improve survival [<xref rid="CIT0002" ref-type="bibr">2</xref>]. The lack of mortality benefit in the current study, despite the observed improvement in cardiac output, highlights a critical challenge in septic shock management: improving surrogate hemodynamic endpoints does not always translate to improved patient-centred outcomes. This underscores the need for caution when interpreting studies that focus primarily on hemodynamic parameters, and it reinforces the importance of prioritizing outcomes such as mortality in clinical trials.</p><p>Second, Tongyoo et&#x000a0;al. performed several subgroup analyses to explore whether the effect of milrinone on cardiac output varied across different patient populations. While the authors reported significant cardiac index improvements in certain subgroups (e.g. older patients, males, those with lower baseline cardiac index), subgroup analyses are inherently prone to false-positive findings [<xref rid="CIT0003" ref-type="bibr">3</xref>]. As Altman and Bland [<xref rid="CIT0003" ref-type="bibr">3</xref>] have explained, subgroup effects are often overemphasized, and statistically significant findings in subgroups should be interpreted with extreme caution, especially when the overall trial shows no effect. The potential for spurious findings is particularly high when multiple subgroups are examined, as was the case in the Tongyoo et&#x000a0;al. study. Therefore, the authors&#x02019; conclusions regarding the differential effects of milrinone in these subgroups should be viewed as exploratory and hypothesis-generating, rather than definitive. These findings require confirmation in larger, adequately powered studies specifically designed to test these subgroup effects.</p><p>In conclusion, while Tongyoo et&#x000a0;al. provide valuable data on the hemodynamic effects of milrinone in septic shock, the absence of a mortality benefit and the limitations of the subgroup analyses warrant careful interpretation of the study&#x02019;s findings. Clinicians should be cautious in extrapolating the observed improvements in cardiac output to improved patient outcomes. Future research should prioritize patient-centred outcomes, including mortality, and avoid overemphasizing subgroup analyses.</p></body><back><sec sec-type="COI-statement" disp-level="1" id="S0003"><title>Disclosure statement</title><p>No potential conflict of interest was reported by the author(s).</p></sec><sec sec-type="data-availability" disp-level="1" id="S0004"><title>Data availability statement</title><p>Data sharing is not applicable to this article as no data were created or analysed in this study.</p></sec><ref-list><title>References</title><ref id="CIT0001"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tongyoo</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Chobngam</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Yolsiriwat</surname>
<given-names>N</given-names></string-name>, <etal>et&#x000a0;al.</etal></person-group>
<article-title>Effects of adjunctive milrinone versus placebo on hemodynamics in patients with septic shock: a randomized controlled trial</article-title>. <source>Emerg Med</source>. <year>2025</year>;<volume>1&#x02013;11</volume>. (p. 7&#x02013;8)</mixed-citation></ref><ref id="CIT0002"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>The ALBIOS Study Investigators</collab></person-group>. <article-title>Albumin replacement in patients with severe sepsis or septic shock</article-title>. <source>N Engl J Med</source>. <year>2014</year>;<volume>370</volume>(<issue>15</issue>):<fpage>1412</fpage>&#x02013;<lpage>1421</lpage>.<pub-id pub-id-type="pmid">24635772</pub-id>
</mixed-citation></ref><ref id="CIT0003"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Altman</surname>
<given-names>DG</given-names></string-name>, <string-name><surname>Bland</surname>
<given-names>JM.</given-names></string-name></person-group>
<article-title>Interaction revisited: the difference between two estimates</article-title>. <source>BMJ</source>. <year>2003</year>;<volume>326</volume>(<issue>7382</issue>):<fpage>219</fpage>&#x02013;<lpage>219</lpage>. doi: <pub-id pub-id-type="doi">10.1136/bmj.326.7382.219</pub-id>.<pub-id pub-id-type="pmid">12543843</pub-id>
</mixed-citation></ref></ref-list></back></article>